A British Journal of Cancer analysis suggests that the timing of immune checkpoint inhibitor administration can influence survival in advanced cancer. Using a large, single-centre cohort, researchers evaluated overall survival not only by whether immunotherapy worked, but by when it was delivered. The work moves beyond the standard binary framing of response to immunotherapy and instead treats dosing schedule as a potential determinant of outcomes. For oncology teams, the study adds impetus to scrutinize real-world treatment timing—particularly around sequencing with other therapies. Because this is presented as an observational reanalysis, it remains most actionable as a hypothesis generator for future prospective work and for internal protocol reviews.